PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canada

K.C Young,H Sandhu,A Lee,K Lakhdari,J Maervoet,C Jones,Y Yuan,M Chaudhary,J.R Penrod,N Varol

doi:10.1016/j.jval.2021.04.274

PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canada

K.C Young, H Sandhu + Show 8 more

Open Access

https://doi.org/10.1016/j.jval.2021.04.274

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 1, 2021
License type: publisher-specific-oa

Affiliation: PAREXEL International (United Kingdom), Bristol-Myers Squibb (United Kingdom), Bristol-Myers Squibb (Canada), Bristol-Myers Squibb (United States)

#Cycles Of Platinum Doublet Chemotherapy #Chemotherapy In First-line Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To evaluate the cost-effectiveness of nivolumab plus ipilimumab in combination with two cycles of platinum doublet chemotherapy (NIVO+IPI+PDC) versus four cycles of platinum doublet chemotherapy (PDC) in first-line (1L) treatment for stage IV or recurrent non-small cell lung cancer (NSCLC) from a Canadian healthcare payer perspective.

Full Text